Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - Hongye Futures has the highest A/H premium at 208.79%, with its A-shares closing at 12.3 yuan, up 1.74%, and H-shares at 4.35 HKD, up 3.33% [1] - Hongye Futures Co., Ltd. was established in 1995 and is a state-owned enterprise fully owned by Jiangsu Provincial State-owned Assets Supervision and Administration Commission [1] Group 2 - The company operates in various sectors including commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, and fund sales [1] - Hongye Futures has established 38 branches in major financial centers and key cities across China, ranking among the top in the country [1] - The company has received multiple honors, including "National Civilized Unit" and "China's Best Futures Company" [1]

Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - China Oilfield Services Limited (COSL) has an AH premium of 117.32%, ranking 22nd among AH shares [1] - COSL's A-shares closed at 13.87 yuan with a gain of 0.22%, and H-shares closed at 6.97 HKD, up by 0.58% [1] Group 2 - COSL is a major integrated oilfield service provider globally, offering services across all stages of offshore oil and gas exploration, development, and production [1] - The company's services are categorized into four main types: geophysical exploration services, drilling services, oilfield technical services, and marine services [1] - COSL was publicly listed on the Hong Kong Stock Exchange on November 20, 2002, and has been trading in the U.S. OTC market since March 26, 2004, and on the Shanghai Stock Exchange since September 28, 2007 [1]

Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - Fudan Zhangjiang's A/H premium reached 177.33%, ranking fourth among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.92 yuan, down 0.27%, and H-shares closed at 4.3 HKD, up 1.65% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic technology drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1]

Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - Longyuan Power's A/H share premium reached 156.68%, ranking ninth among A/H shares [1] - Longyuan Power's A-shares closed at 16.5 yuan, with a gain of 0.61%, and H-shares closed at 7.02 HKD, up by 0.57% [1] Group 2 - Longyuan Power Group Co., Ltd. was established in 1993 and has undergone several ownership changes, currently under the State Energy Group [1] - The company successfully listed on the Hong Kong main board in 2009 and was recognized as "China's first new energy stock" [1] - In 2022, Longyuan Power officially listed on the A-share market, marking several firsts in the industry, including being the first H-share new energy power central enterprise to return to A-shares [1] - Longyuan Power is a pioneer in wind power development in China, leading in offshore, low wind speed, and high altitude wind power sectors [1] - Since 2015, Longyuan Power has maintained its position as the world's largest wind power operator [1]

Core Points - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - China Merchants Industry Holdings Co., Ltd. (the "Company") has an A/H premium of 128.51%, ranking 15th among A/H shares [1] - The Company’s A-shares closed at 2.49 yuan, with a gain of 0.4%, and H-shares closed at 1.19 HKD, up by 2.59% [1] Company Overview - The Company is a subsidiary of China Ocean Shipping Group Co., Ltd. and specializes in shipping logistics and financial operations [1] - Established in 1997 and headquartered in Shanghai, the Company is listed in both Hong Kong and Shanghai [1] - The Company focuses on container manufacturing, leasing, and shipping leasing, supported by investment management for integrated development [1] Business Operations - The container manufacturing segment engages in the research, development, production, and sales of international standard dry cargo containers, refrigerated containers, and special containers [1] - The Company has an annual production capacity exceeding 1.4 million TEUs, making it the second-largest in the world [1] - The customer base includes globally recognized shipping companies and major leasing firms [1] - The Company aims to enhance its core competitiveness through technological innovation and green low-carbon transformation, aspiring to become a world-class logistics equipment technology enterprise [1]

Core Viewpoint - The article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on August 5, with notable movements in the stock prices of China Aluminum International Engineering Corporation (referred to as "China Aluminum International") and its A/H share premium status [1] Group 1: Market Performance - On August 5, the Shanghai Composite Index rose by 0.96%, closing at 3617.6 points, while the Hang Seng Index increased by 0.68%, closing at 24902.53 points [1] - China Aluminum International's A-share closed at 4.84 yuan, with a gain of 0.62%, and its H-share closed at 2.39 Hong Kong dollars, up by 1.27% [1] Group 2: Company Overview - China Aluminum International was established on December 16, 2003, and is a subsidiary of China Aluminum Group, focusing on engineering technology services [1] - The company is located in Haidian District, Beijing, and holds a comprehensive Class A engineering design qualification, positioning itself as a leading provider of technology, engineering services, and equipment in the non-ferrous metals industry [1] - China Aluminum International was listed on the Hong Kong Stock Exchange on July 6, 2012 (H-share code: 02068.HK) and on the Shanghai Stock Exchange on August 31, 2018 (A-share code: 601068.SH), becoming the first A+H share company in the non-ferrous engineering technology sector [1] Group 3: A/H Share Premium - The A/H share premium for China Aluminum International reached 121.15%, ranking it 18th among companies with A/H share premiums [1] - A higher A/H share premium indicates that the H-shares are relatively cheaper compared to A-shares [1]

Investment Rating - The industry investment rating is "Positive" and is maintained [8] Core Insights - The report highlights that the AH premium rates for A/H listed pharmaceutical companies remain at a high level, with significant premiums observed for various innovative drug companies and CXO firms as of August 1, 2025 [2][6] - The report indicates a trend of narrowing AH premium rates, suggesting that leading companies like Heng Rui Medicine and WuXi AppTec have begun to achieve valuation recovery, with Heng Rui's H shares experiencing a reversal in AH premium [7][28] - The report anticipates that as Chinese innovative pharmaceutical companies continue to advance their R&D pipelines and internationalization efforts, the Hong Kong stock market may enter a value reassessment phase, revealing structural investment opportunities [2][28] Summary by Sections AH Premium Rates - As of August 1, 2025, the AH premium rates for several innovative drug companies are as follows: BeiGene at 47.56%, Junshi Biosciences at 70.30%, Innovent Biologics at 83.37%, Fudan-Zhangjiang at 185.15%, and Rongchang Biologics at 17.36% [6][17] - For CXO companies, the AH premium rates are: Zhaoyan New Drug at 52.67%, Tigermed at 36.50%, Kanglong Chemical at 51.60%, and Kelaiying at 20.21% [6][17] Trends in AH Premium Rates - The report notes a significant decrease in AH premium rates since early 2025, with leading companies like Heng Rui Medicine and WuXi AppTec achieving notable valuation adjustments [7][23] - The AH premium rates for these companies have shown a marked decline from earlier levels, indicating a shift in market dynamics [23][28] Investment Perspectives - The report emphasizes that the ongoing "tenglong huan niao" (transformation) in medical insurance will continue to unfold, with innovative drugs being a primary investment focus [30] - It suggests that companies with healthy cash flows, strong innovation capabilities, and established R&D platforms are well-positioned for growth [30] - The report also highlights the importance of breakthrough therapies and technological advancements, particularly in areas such as cytokine immunotherapy and PD1-based therapies [30]

8月4日，上证指数涨0.66%，收报3583.31点，恒生指数涨0.92%，收报24733.45点。 中船防务AH溢价达91.53%，位居AH股溢价率第37位。当日收盘，中船防务A股报28.19元，涨幅 3.3%，H股报16.1港元，上涨7.33%。 本文源自：金融界 资料显示，中船海洋与防务装备股份有限公司是中国船舶集团有限公司属下的大型造船骨干企业之一, 其前身是广州广船国际股份有限公司。公司于1993年在上海和香港上市,是中国第一家A+H股上市造船 企业。 为推动行业兼并整合,实现战略性产能布局,增强综合竞争力,2014年、2015年,中船防务先后收购 了中船龙穴造船有限公司、中船黄埔文冲船舶有限公司,完成了对中船集团在华南地区优质造船资产的 整合,成为集海洋防务装备、海洋运输装备、海洋开发装备和海洋科考装备四大海洋装备于一体的大型 综合性海洋与防务装备企业集团。 今天,中船防务已经描绘出了致力于"成为全球海洋与重型装备市场技 术领先、服务卓越的一流企业"的宏伟蓝图。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 作者：行情君 ...

Core Viewpoint - The article highlights the performance of Zhejiang Shibao Co., Ltd., which has a significant A/H share premium and is recognized as a leading enterprise in the automotive steering system industry in China [1][2]. Company Overview - Zhejiang Shibao Co., Ltd. was established in 1984 and focuses on the research, development, manufacturing, and sales of automotive steering system products [1]. - The company was recognized as a "leading enterprise in the automotive steering gear industry" by the China Association of Automobile Manufacturers in 2009 and has been a key participant in setting steering gear standards in China [1]. - It has been awarded the title of "one of the top 100 excellent automotive parts suppliers in the country" for several consecutive years [1]. Business Strategy - The company adheres to a business philosophy of "pragmatism and innovation," continuously introducing advanced technologies and production testing equipment [1]. - It gathers domestic and international experts, technical talents, and management elites to enhance its operational capabilities [1]. - The implementation of lean production management aims to provide high-quality products and excellent services to both domestic and international customers [1]. Market Position - Zhejiang Shibao aims to develop into an internationally recognized brand in automotive steering systems and to become a long-term trusted partner for many well-known automobile manufacturers globally [1].

Group 1 - The Shanghai Composite Index rose by 0.66% to close at 3583.31 points, while the Hang Seng Index increased by 0.92% to 24733.45 points [1] - The premium of Haiprui's A-shares over H-shares reached 131.61%, ranking 14th among AH shares in terms of premium rate [1] - Haiprui's A-shares closed at 13.17 yuan, down 0.6%, and H-shares closed at 6.22 Hong Kong dollars, remaining flat [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company operates across the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic and driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]